FDA plans to speed path to approval for some gene therapies, starting with hemophilia
Hemophilia is the first disease the FDA will target with its new policy.
WASHINGTON — The Food and Drug Administration will soon be alerting companies that certain gene therapies in development can qualify for less arduous review at the agency, Commissioner Scott Gottlieb said Tuesday.
Specifically, gene therapies for , a rare disease in which blood doesn’t
